Competitive Technologies

Competitive Technologies
Dade Behring

August 30, 2005 17:00 ET

Competitive Technologies Licenses Homocysteine Assay to Dade Behring

FAIRFIELD, Conn. & DEERFIELD, Ill.--(CCNMatthews - Aug 30, 2005) -

Competitive Technologies, Inc. (AMEX: CTT) and Dade Behring Holdings Inc. (NASDAQ: DADE) today announced that a homocysteine assay license has been granted to Dade Behring Inc. under CTT's U.S. Patent Number 4,940,658 and its foreign counterparts, relating to homocysteine medical tests. Pursuant to the license, Dade Behring will pay CTT an initial, upfront license fee and a per test royalty on sales of homocysteine assay products.

Elevated levels of homocysteine resulting from Vitamin B12 and folate deficiency may be a risk factor in heart attacks, strokes, blood clots, various pregnancy complications, dementia from Alzheimer's, rheumatoid arthritis, osteoporosis and presbyopia. The homocysteine patent is derived from discoveries made by CTT's clients, Drs. Robert Allen and Sally Stabler from the University of Colorado, and the late Dr. John Lindenbaum from Columbia University.

"We are very pleased to issue this license to Dade Behring, a global leader in clinical diagnostics," said Aris D. Despo, CTT's Senior Vice President, Life Sciences. "This new license continues the growth trend of CTT's very successful licensing and royalty collection program for our patented homocysteine assay."

"As a global leader in the cardiac diagnostic marketplace, Dade Behring is extremely pleased to license homocysteine and be able to add a new test to our growing portfolio of cardiac diagnostic tests, markers and licenses," said Jim Reid-Anderson, Chairman, President and CEO, Dade Behring. "The management of cardiovascular disease is the world's number one health issue, and Dade Behring is committed to helping clinicians find the best way to manage and assess cardiovascular disease in their patients and thus significantly improve patient outcomes."

About Dade Behring

With 2004 revenues of nearly $1.6 billion, Dade Behring is the world's largest company dedicated solely to clinical diagnostics. It offers a wide range of products, systems and services designed to meet the day-to-day needs of labs, delivering innovative solutions to customers and enhancing the quality of life for patients. Visit Dade Behring's website:

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life and physical sciences, electronics, and nanotechnologies developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website:

Statements about our future expectations, including development and regulatory plans, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. If and when used herein, the words "anticipate," "believe," "intend," "plan," "expect," "estimate," "approximate," and similar expressions, as they relate to us or our business or management, are intended to identify such forward-looking statements. These statements involve risks and uncertainties related to market acceptance of and competition for our licensed technologies, growth strategies, operating performance, industry trends, and other risks inherent in our business, including those set forth in Item 7 under the caption "Risk Factors," in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on October 29, 2004, and other factors that may be described in our other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.

Contact Information